Logo image of CDIO

CARDIO DIAGNOSTICS HOLDINGS (CDIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CDIO - US14159C2026 - Common Stock

2.9 USD
+0.01 (+0.35%)
Last: 12/2/2025, 4:04:06 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CDIO. CDIO was compared to 534 industry peers in the Biotechnology industry. The financial health of CDIO is average, but there are quite some concerns on its profitability. CDIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CDIO had negative earnings in the past year.
CDIO had a negative operating cash flow in the past year.
In the past 5 years CDIO always reported negative net income.
In the past 5 years CDIO reported 4 times negative operating cash flow.
CDIO Yearly Net Income VS EBIT VS OCF VS FCFCDIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M

1.2 Ratios

With a Return On Assets value of -60.12%, CDIO perfoms like the industry average, outperforming 43.07% of the companies in the same industry.
CDIO has a Return On Equity (-64.27%) which is in line with its industry peers.
Industry RankSector Rank
ROA -60.12%
ROE -64.27%
ROIC N/A
ROA(3y)-113.75%
ROA(5y)-106.63%
ROE(3y)-159.76%
ROE(5y)-310.78%
ROIC(3y)N/A
ROIC(5y)N/A
CDIO Yearly ROA, ROE, ROICCDIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

CDIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CDIO Yearly Profit, Operating, Gross MarginsCDIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

5

2. Health

2.1 Basic Checks

CDIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CDIO has been increased compared to 1 year ago.
CDIO has a better debt/assets ratio than last year.
CDIO Yearly Shares OutstandingCDIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 500K 1M 1.5M
CDIO Yearly Total Debt VS Total AssetsCDIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

CDIO has an Altman-Z score of 0.20. This is a bad value and indicates that CDIO is not financially healthy and even has some risk of bankruptcy.
CDIO's Altman-Z score of 0.20 is fine compared to the rest of the industry. CDIO outperforms 61.80% of its industry peers.
CDIO has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
CDIO has a Debt to Equity ratio (0.01) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 0.2
ROIC/WACCN/A
WACC8.5%
CDIO Yearly LT Debt VS Equity VS FCFCDIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M

2.3 Liquidity

CDIO has a Current Ratio of 23.55. This indicates that CDIO is financially healthy and has no problem in meeting its short term obligations.
CDIO has a Current ratio of 23.55. This is amongst the best in the industry. CDIO outperforms 97.00% of its industry peers.
CDIO has a Quick Ratio of 23.55. This indicates that CDIO is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 23.55, CDIO belongs to the best of the industry, outperforming 97.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 23.55
Quick Ratio 23.55
CDIO Yearly Current Assets VS Current LiabilitesCDIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 50.00% over the past year.
Looking at the last year, CDIO shows a very negative growth in Revenue. The Revenue has decreased by -50.13% in the last year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.06%
Revenue 1Y (TTM)-50.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-4.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
CDIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 2032.01% yearly.
EPS Next Y22.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
CDIO Yearly Revenue VS EstimatesCDIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 5M 10M 15M 20M 25M
CDIO Yearly EPS VS EstimatesCDIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CDIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CDIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CDIO Price Earnings VS Forward Price EarningsCDIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CDIO Per share dataCDIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CDIO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARDIO DIAGNOSTICS HOLDINGS

NASDAQ:CDIO (12/2/2025, 4:04:06 PM)

2.9

+0.01 (+0.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12
Earnings (Next)03-18 2026-03-18
Inst Owners4.81%
Inst Owner Change-12.12%
Ins Owners4.04%
Ins Owner Change0%
Market Cap5.31M
Revenue(TTM)19.50K
Net Income(TTM)-6.25M
Analysts82.86
Price Target61.2 (2010.34%)
Short Float %0.26%
Short Ratio0.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)826.47%
Min Revenue beat(2)-90.2%
Max Revenue beat(2)1743.14%
Revenue beat(4)1
Avg Revenue beat(4)369.67%
Min Revenue beat(4)-93.86%
Max Revenue beat(4)1743.14%
Revenue beat(8)1
Avg Revenue beat(8)140.84%
Revenue beat(12)1
Avg Revenue beat(12)60.85%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 272.15
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-9.9
EYN/A
EPS(NY)-7.65
Fwd EYN/A
FCF(TTM)-3.14
FCFYN/A
OCF(TTM)-3.02
OCFYN/A
SpS0.01
BVpS5.31
TBVpS4.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -60.12%
ROE -64.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-113.75%
ROA(5y)-106.63%
ROE(3y)-159.76%
ROE(5y)-310.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.71%
Cap/Sales 1109.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.55
Quick Ratio 23.55
Altman-Z 0.2
F-Score4
WACC8.5%
ROIC/WACCN/A
Cap/Depr(3y)419.33%
Cap/Depr(5y)421.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.06%
EPS Next Y22.73%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-50.13%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-4.7%
Revenue Next Year854.55%
Revenue Next 2Y2032.01%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y25.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y25.89%
OCF growth 3YN/A
OCF growth 5YN/A

CARDIO DIAGNOSTICS HOLDINGS / CDIO FAQ

What is the fundamental rating for CDIO stock?

ChartMill assigns a fundamental rating of 2 / 10 to CDIO.


Can you provide the valuation status for CARDIO DIAGNOSTICS HOLDINGS?

ChartMill assigns a valuation rating of 0 / 10 to CARDIO DIAGNOSTICS HOLDINGS (CDIO). This can be considered as Overvalued.


How profitable is CARDIO DIAGNOSTICS HOLDINGS (CDIO) stock?

CARDIO DIAGNOSTICS HOLDINGS (CDIO) has a profitability rating of 1 / 10.


How financially healthy is CARDIO DIAGNOSTICS HOLDINGS?

The financial health rating of CARDIO DIAGNOSTICS HOLDINGS (CDIO) is 5 / 10.